Lyell Immunopharma Inc (LYEL) — Cash Flow-to-Debt Ratio
Latest as of December 2025:
-0.35x
Lyell Immunopharma Inc (LYEL) has a Cash Flow-to-Debt Ratio of -0.35x as of December 2025, meaning its operating cash flow of $-32.25 Million could theoretically repay 0% of its total liabilities ($91.85 Million) in one year. See LYEL FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.35x
Operating CF / Total Liabilities
Operating Cash Flow
$-32.25 Million
USD
Total Liabilities
$91.85 Million
USD
Data as of
Dec 2025
Most recent filing
Lyell Immunopharma Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Lyell Immunopharma Inc across 7 annual periods. For the full cash flow conversion analysis, see how efficiently does Lyell Immunopharma Inc generate cash.
Annual Cash Flow-to-Debt Ratio for Lyell Immunopharma Inc (2019–2025)
Year-by-year debt coverage analysis for Lyell Immunopharma Inc.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.63x | $-150.02 Million | $91.85 Million | ▼ -8.7% |
| 2024 | -1.50x | $-162.39 Million | $108.03 Million | ▲ +12.7% |
| 2023 | -1.72x | $-163.69 Million | $95.08 Million | ▼ -5.9% |
| 2022 | -1.63x | $-169.56 Million | $104.31 Million | ▼ -154.4% |
| 2021 | -0.64x | $-126.25 Million | $197.62 Million | ▲ +24.6% |
| 2020 | -0.85x | $-160.87 Million | $189.84 Million | ▼ -416.8% |
| 2019 | 0.27x | $39.47 Million | $147.58 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.